Figure 1

The activation of GPR30 inhibited the proliferation of ER− breast cancer cells. (a) SkBr3 and MDA-MB-231 cells were treated with various concentrations (10−8 to 10−5 M) of G-1 for 48 h, and then cell viability was assessed by CCK-8 kit. (b) SkBr3 and MDA-MB-231 cells were treated with 1 μM G-1 for 24, 36, and 48 h, respectively, and then cell viability was assessed by CCK-8 kit. (c) After 24 h pre-transfection with si-NC or si-GPR30 siRNAs, the protein levels of GPR30 were analyzed by western blotting. (d) After 24 h pre-transfection with si-NC or si-GPR30 siRNAs, SkBr3 or MDA-MB-231 cells were further treated with 1 μM G-1 for 48 h, and then cell viability was assessed by CCK-8 kit. Data were presented as means±S.D. of three independent experiments (ten independent experiments for cell viability). *P<0.05 compared with control; **P<0.01 compared with control